Icelandic Salmon (ISLAX) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
17 Dec, 2025Executive summary
Q4 2024 saw stabilized biological conditions, higher harvest volumes and weights, and effective sea lice control, with strong price performance in key markets, especially North America and Asia.
Full year 2024 harvest was 11,676 tonnes, down from 17,919 tonnes in 2023, due to biological challenges in late 2023 and early 2024.
Q4 harvest volume was 6,455 tonnes, down from 7,219 tonnes in Q4 2023, reflecting MAB optimization and recovery from earlier challenges.
The company operates throughout the value chain, with four smolt facilities and eight farming sites, present in both domestic and global markets.
EBIT for Q4 was EUR 1.4 million, compared to EUR 2.0 million in Q4 2023, impacted by lower harvest volumes and earlier biological challenges.
Financial highlights
Q4 2024 operating income was EUR 49.9 million, down from EUR 51.6 million in Q4 2023, mainly due to lower harvest volumes.
Operational EBIT margin was 3% in Q4 2024, compared to 4% in Q4 2023.
Operational EBIT per kg (excluding one-offs) was EUR 0.31 in Q4 2024, down from EUR 1.00 in Q4 2023.
Net interest-bearing debt including leasing was EUR 86.8 million at year-end, down EUR 2.5 million over the period.
Positive EBITDA of EUR 5.5 million and improved working capital in Q4 2024.
Outlook and guidance
2025 volume guidance maintained at 15,000 tonnes, with most harvest expected in H2 2025 and significant biomass increase anticipated.
Full year 2025 cost level expected to be lower than 2024, driven by increased volume and lower feed cost.
Long-term ambition is to reach 26,000 tonnes per year within existing licenses and regulatory framework.
Conservative approach to 2025 volume guidance due to prior year experience and ongoing biological challenges.
High cost level and low volume expected in H1 2025; contract share expected at ~10% for FY 2025.
Latest events from Icelandic Salmon
- Q4 2025 delivered improved profitability and sets up a 67% volume growth for 2026.ISLAX
Q4 202510 Feb 2026 - Operational loss from high costs, but harvest growth and 2026 recovery expected.ISLAX
Q3 202510 Feb 2026 - Biological setbacks drove Q2 and H1 losses, but new licenses and ASC certification support growth.ISLAX
Q2 202423 Jan 2026 - Harvest and EBIT were low in Q3, but strong demand and higher volumes are expected in Q4.ISLAX
Q3 202414 Jan 2026 - Biological setbacks and weak prices drove a Q1 2025 loss, but 2025 guidance is unchanged.ISLAX
Q1 202525 Nov 2025 - Operational losses and lower guidance amid biological, regulatory, and market challenges.ISLAX
Q2 202523 Nov 2025